KRAS, EGFR, and STAT3 Inhibitor Combination Achieves Complete, Durable Pancreatic Cancer Regression

Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers, characterized by extremely low survival rates. A major challenge in treating PDAC is the high prevalence of activating KRAS mutations, which drive tumor initiation and progression. While recent advancements in RAS inhibitors have shown promise, their clinical efficacy is often limited by the rapid development of tumor resistance. This necessitates novel therapeutic strategies that can overcome these resistance mechanisms and provide more durable responses, targeting multiple critical pathways involved in PDAC pathogenesis.

Researchers first demonstrated that genetic ablation of three key signaling nodes—downstream (RAF1), upstream (EGFR), and orthogonal (STAT3) to KRAS—resulted in complete and permanent regression of orthotopic PDACs induced by Kras/Tp53 mutations. Building on this, they tested a combination therapy using selective inhibitors: RMC-6236/daraxonrasib (a KRAS inhibitor), afatinib (an EGFR family inhibitor), and SD36 (a STAT3 inhibitor). This combination was administered to orthotopic PDAC tumor models, genetically engineered mouse (GEM) tumors, and patient-derived xenografts (PDX). The primary endpoints were tumor regression and the prevention of tumor resistance, with observations extending over 200 days post-treatment.

Genetic ablation of RAF1, EGFR, and STAT3 pathways led to complete and permanent regression of orthotopic PDACs, highlighting the critical role of these nodes. Crucially, the targeted combination therapy mirrored these results: > The combination of RMC-6236/daraxonrasib, afatinib, and SD36 induced complete regression of orthotopic PDAC tumors with no evidence of tumor resistance for over 200 d post-treatment. This sustained response indicates a significant breakthrough in overcoming the notorious resistance of PDAC. The therapy also achieved significant regression in genetically engineered mouse tumors and patient-derived tumor xenografts (PDX), further validating its broad efficacy across different preclinical models. Importantly, the combination therapy was reported to be well tolerated, suggesting a favorable safety profile in these models, which is a critical factor for clinical translation.